We are excited to announce our feature in the prestigious MedNous journal, as highlighted by Jean-Claude Müller. This publication, stemming from insightful discussions at the J.P. Morgan conference, delves into recent advancements in biotechnology for auditory health.
Here’s a sneak peek into the highlights of the article:
- Awareness of the crucial importance of hearing in cognitive decline and dementia has been spurred by several factors: demographic aging, noise exposure, ototoxic effects of medications, and the increasing prevalence of chronic illnesses…
- However, hearing loss, leading to social isolation, decreased quality of life, reduced productivity, and depressive symptoms, represents a staggering economic burden estimated at $980 billion by the WHO.
- But there’s good news! While hearing loss used to take a back seat in the biopharmaceutical industry, the rise of biotechnology brings new perspectives.
- With a better understanding of auditory disorders and the discovery of the potential of biological interventions in neurological conditions, the landscape is changing.
- Today, the ecosystem is buzzing. Among others, forty entities, including Cilcare, are now dedicated to developing novel therapies for hearing loss.
- Moreover, the development of digital biomarkers and AI algorithms will enable the diagnosis and prediction of hearing loss and associated diseases. In short, it’s poised to revolutionize medicine!
To delve into this captivating article, we invite you to subsribe to MedNous Journal : https://www.mednous.com/treating-hearing-loss-people-age
